Access and Global Health

Access and Global Health

We believe in healthcare as it should be – empowering people worldwide to live healthier at every stage of life. Because of our unwavering belief that better access leads to better health, we leverage our best-in-class manufacturing and scientific expertise and proven commercial capabilities to bring high-quality medicines to patients when and where they need them.

CORPORATE SOCIAL RESPONSIBILITY

Working for Patient Access

Our company’s commitment to sustainable access to high-quality medicines is fundamental to our mission of empowering people worldwide to live healthier at every stage of life. We believe strongly in doing our part to build a better future by helping tackle some of the world’s complex health problems. To address the overall burden of disease, we go beyond making and distributing medicine to also building public awareness, supporting research and access to education, and pursuing innovative solutions for a holistic approach to prevention and treatment.

To help ensure access and strengthen the resilience of healthcare systems, we have set initial companywide goals around access to HIV treatment for adults and children and patient impact via healthcare professional training:

Provide antiretroviral (ARV) therapy equivalent to a total of 30 million patients, including more than 2 million children living with HIV/AIDS, between 2022 and the end of 2025.
Impact 100 million patients via healthcare professional (HCP) education and outreach regarding prevention, diagnosis and treatment options for cardiovascular disease, diabetes, cancer and other important chronic conditions to improve outcomes through the NCD Academy by the end of 2025.

Sustainable Access and Global Health

In 2021, the COVID-19 pandemic continued to have huge direct and indirect implications for patients and healthcare systems around the world. Pre-existing inequities were amplified, vulnerabilities revealed, and the urgency of building more resilient healthcare systems has become even more profound. Patients in lower-income countries and settings have been hit especially hard.

Ensuring sustainable access to medicine and empowering people to live healthier requires a multipronged approach that includes a global, diversified and reliable supply of medicine delivered via a broad and differentiated portfolio across geographies, policy solutions that remove barriers to medicine and care, greater regulatory harmony, disease awareness among patients and healthcare providers, and strong partnerships that address local patient needs while strengthening global public health.

Serving Patients

We truly believe that through our capabilities and partnerships, serving patients in more than 165 countries and territories, we can contribute to progress on the sustainable development goal #3 - health and wellbeing for all.

80BN+

doses sold in 2021

~90% Reach

of low- and lower-middle income countries

Driving Policy Solutions for Equitable Access

An important part of driving access to high-quality, more affordable medicines for patients is breaking complex regulatory, policy and economic barriers while ensuring quality and patient safety. That entails working to support harmonization of different frameworks and economic models that preserve and advance access to high-quality medicines; building healthier markets that can sustain access in years to come; and strengthening an interconnected, global and resilient supply chain where domestic production does not impede the ability of health systems to respond to the ongoing needs of patients.

Learn more

“I truly believe that Viatris has an important role to play in addressing unmet needs and gaps in treatment to help improve the reality for the millions of people worldwide who deserve better access to medicine.”

Abhijit Barve, Chief Medical Officer, Viatris

Working to Make a Difference

We go beyond making and distributing medicine to also building public awareness, supporting research and access to education and pursuing innovative solutions for a holistic approach to prevention and treatment.

NCDs - Viatris’ portfolio helps address the burden of NCDs. Via our commercial footprint and partnerships, we seek to leverage our portfolio to bring access and other services to patients and healthcare systems across the world.

A Historic Approval for US Patients - In July 2021, Viatris and Biocon Biologics received approval from the U.S. Food and Drug Administration for Semglee^® (insulin glargine-yfgn) injection, the first interchangeable biosimilar product in the U.S. under the new 351(k) regulatory pathway.

Fighting Infectious Disease - As the pandemic has put a great strain on health systems and resources, care has been disrupted for many through delays in testing, treatment and other services. This is especially concerning in low-income countries, where six of the top 10 causes of death are infectious diseases.

Addressing AMR Viatris is committed to doing our part to address antimicrobial resistance (AMR) and advance appropriate access to antimicrobials. Fighting AMR requires a multipronged approach – access, stewardship, and responsible manufacturing.

Making a Difference

Our 2021 Sustainability Report details our commitments to stakeholders as we seek to empower people worldwide to live healthier at every stage of life.

Read the report

Viatris 2021 Sustainability Report Fact Sheet

A letter from our CEO Michael Goettler

Localized information for

Localized information for

Leaving this page